
Cassel Salpeter & Co.’s Q3 healthcare update points to disrupted NIH grant processing, FDA attrition, and tariffs as pressures on drug development and early-stage financing.
Exhibitor Profiles from the DIA meeting hall
Click
over 20 years ago
BBK Healthcare, Inc. Evolves to Become BBK Worldwideover 20 years ago
Datafarm Announces the Release of Web-Based eCTD Viewer





